Ovid Therapeutics (NASDAQ: OVID) shares surged over 18% today following promising data from a Phase 1 study of its next-generation epilepsy treatment, OV329. This GABA-aminotransferase (GABA-AT) inhibitor aims to address rare and treatment-resistant forms of epilepsy, offering a potential alternative to the first-generation drug Vigabatrin, which carries severe side effects, including the risk of permanent vision loss.
The Phase 1 trial results highlighted that the 7 mg dose of OV329 showed no treatment-related adverse events and no ophthalmic changes, indicating a favorable safety profile. This positive outcome is crucial for healthcare investors, as it reinforces management’s claims of OV329’s enhanced potency and tolerability compared to existing treatments. Additionally, Ovid plans to utilize a $60 million private placement to further develop OV329 for other seizure indications.
Investors should closely monitor Ovid’s next steps, particularly the upcoming Phase 2 trial for drug-resistant focal onset seizures. For a deeper dive into this development, I recommend checking out the full article.
Source: fool.com